Esperion Therapeutics (NASDAQ:ESPR) Rating Reaffirmed
In a note shared with investors and clients this morning, RBC Capital Mkts reaffirmed their “Outperform” rating on Esperion Therapeutics (NASDAQ:ESPR) shares. The Estimated Target Price suggests a possible upside of 68.99% from company’s previous stock close.
From a total of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 85% of the ratings are positive. The highest target price is $115 while the lowest target price is $18. The mean of all analyst targets is $72 with a 213.39% above today’s ($23.67) stock price. Esperion Therapeutics was the topic of 18 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. RBC Capital Markets maintained shares on November 6 with “Outperform” rating. Needham upgraded shares to “Buy” rating and $130.0 target share price in a report from an August 10. WallachBeth Capital initiated ESPR stock in a recent report from October 26 with “Buy” rating. Finally, Zacks downgraded the stock to “Hold” rating in a report issued on a September 4.
The stock decreased 5.43% or $1.36 during the last trading session, striking $23.67. Approximately shares of stock traded hands. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 77.59% since May 12, 2015 and is downtrending. It has underperformed by 73.91% the S&P500.
The overall sentiment of institutions has decreased to 0.87 in Q2 2015. Its down 0.90, from 1.77 in 2015Q2. The ratio turned negative, as 53 institutions have sold all the shares of Esperion Therapeutics Inc that they owned while 30 funds have taken shares off the table. 24 funds have purchased shares for the first time while 48 added to their positions. These institutions now hold 25.07 million shares or 49.87% more than the 16.72 million shares they owned in 2015Q2.
The Fund Aisling Capital Llc currently is holding shares equating to 6.79% of its total portfolio in Esperion Therapeutics Inc representing a total of 1.64 million shares. Another fund,Sarissa Capital Management Lp, is holding a total of 448,000 shares equating to 2.61% of their holdings. Additionally, Bb Biotech Ag has a 908,542 share stake in Esperion Therapeutics Inc which represents 0.68% of their total portfolio. The Fund, First Light Asset Management Llc, based out of Minnesota, has also built up a stake in the stock, which represents a total of 0.56% of their total portfolio. Finally Iguana Healthcare Management Llc, a fund which is based in the state of New York reported a total holdings of 50,000 shares.
Esperion Therapeutics, Inc. is a pharmaceutical firm focused on developing and commercializing oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The company has a market cap of $563.65 million. The Company’s primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. It currently has negative earnings. ETC-1002, the Company’s lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available.
According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”